Merck Canada Inc.
18 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
11
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 14, 2027The maintenance fee for HIV protease inhibitors (US 9,079,834) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for HIV protease inhibitors (US 9,133,157) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due Apr 27, 2027The maintenance fee for Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase (US 9,168,248) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
- 1 fee due May 17, 2027The maintenance fee for Sulfonamides as HIV protease inhibitors (US 9,187,415) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,696,222 | Indole derivatives as CRTH2 receptor antagonists In force · From the USPTO record | In force | From the USPTO record | |
| US 7,442,716 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 7,705,035 | Indoline amide derivatives as EP4 receptor ligands In force · From the USPTO record | In force | From the USPTO record | |
| US 7,968,578 | Indole amide derivatives as EP4 receptor antagonists In force · From the USPTO record | In force | From the USPTO record | |
| US 7,928,091 | Cathepsin cysteine protease inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,003,661 | Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists In force · From the USPTO record | In force | From the USPTO record | |
| US 8,158,671 | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists In force · From the USPTO record | In force | From the USPTO record | |
| US 8,969,394 | Thiophenecarboxamide Derivatives as EP4 Receptor Ligands In force · High confidence | In force | High confidence | |
| US 8,013,159 | Quinoline Derivatives as EP4 Antagonists In force · High confidence | In force | High confidence | |
| US 8,642,799 | Cysteine protease inhibitors for the treatment of parasitic diseases In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 16: 18 patents in force now held by others · 21 lapsed for an unpaid fee · 30 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 1 no status recorded